CompletedPhase 2NCT06011798
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
Studying Central retinal vein occlusion
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Unity Biotechnology, Inc.
- Principal Investigator
- Robert Bhisitkul, MD, Ph.D.Unity Biotechnology, Inc.
- Intervention
- Aflibercept(drug)
- Enrollment
- 52 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (19)
- California Retina Consultants, Bakersfield, California, United States
- Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
- Salehi Retina Institute Inc., Huntington Beach, California, United States
- Bay Area Retina Associates, Walnut Creek, California, United States
- Advanced Vision Research Institute, Longmont, Colorado, United States
- Rand Eye Institute, Deerfield Beach, Florida, United States
- Florida Eye Associates, Melbourne, Florida, United States
- Retina Vitreous Associates of Florida, St. Petersburg, Florida, United States
- University Retina and Macula Associates, Lemont, Illinois, United States
- Midwest Eye, Carmel, Indiana, United States
- Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
- Sierra Eye Associates, Reno, Nevada, United States
- EyeHealth Northwest, Portland, Oregon, United States
- Erie Retina Research, LLC, Erie, Pennsylvania, United States
- Vision Research Solutions, PLLC, Philadelphia, Pennsylvania, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06011798 on ClinicalTrials.govOther trials for Central retinal vein occlusion
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE4NCT07456826Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsHarrow Inc
- ENROLLING BY INVITATIONNANCT07318428AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and GlaucomaInje University
- RECRUITINGNCT07308639DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.Bayer
- RECRUITINGPHASE2NCT07259928Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein OcclusionAnnexin Pharmaceuticals AB
- RECRUITINGEARLY PHASE1NCT04008121Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein SodiumMediBeacon
- RECRUITINGNCT07550777Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal BevacizumabAtaturk University
- RECRUITINGPHASE2NCT07205887A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVOEyeBiotech Ltd.
- RECRUITINGNANCT07002372Effect of Video Viewing on Intravitreal Injection ExperienceSecond Affiliated Hospital, School of Medicine, Zhejiang University